Viewing Study NCT05005468


Ignite Creation Date: 2025-12-24 @ 5:34 PM
Ignite Modification Date: 2026-03-29 @ 7:20 AM
Study NCT ID: NCT05005468
Status: UNKNOWN
Last Update Posted: 2021-08-13
First Post: 2021-08-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.
Sponsor: Shanghai Chest Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module